SIETES :: 91969 citas

Resultados de la búsqueda por FRAUDE REFINAR BÚSQUEDA

1.

de Boissieu P, Kanagaratnam L, Mahmoudi R, Morel A, Dramé M, Trenque T. Adjudication of osteonecrosis of the jaw in phase III randomized controlled trials of denosumab: a systematic review. Eur J Clin Pharmacol 2017;73:517-23. [Ref.ID 101992]

2.

Ebell MH. WHO downgrades status of oseltamivir. BMJ 2017;358:j3266. [Ref.ID 101981]

3.

Rosenberg HG, Shnier A. Regulatory data are hidden in plain sight. BMJ 2017;358:j3437. [Ref.ID 101980]

4.

Silverman E. US drug regulators should consider adding adults to SSRI suicide warning, says campaigner. BMJ 2017;357:j2050. [Ref.ID 101550]

5.

Anónimo. Lawsuit accuses three drugmakers of conspiring to increase insulin prices. DIA Daily 2017:1. [Ref.ID 101380]

6.

Saiz Fernández LC. Ensayo EMPA-REG OUTCOME (empagliflozina) El poder de la verdad, la verdad del poder.. Boletín de Información Farmacoterapéutica de Navarra 2016;24:1-13. [Ref.ID 101347]

7.

Erviti López J, Saiz Fernández LC, Garjón Parra J. Fiabilidad de los ensayos clínicos. El peligroso camino de la desregulación de los medicamentos. Med Clin (Barc) 2016;147:554-7. [Ref.ID 101012]

8.

Anónimo. Results have not been published for almost half of clinical trials conducted by large pharmaceutical companies. DIA Daily 2016:2. [Ref.ID 100877]

9.

Welch WVa. Secret trove reveals bold ‘crusade’ to make OxyContin a blockbuster. STAT 2016:1. [Ref.ID 100698]

10.

Anónimo. FDA commissioner calls for eteplirsen study to be retracted as “misleading.”. DIA Daily 2016:4. [Ref.ID 100697]

11.

12.

Dyer O. Drug companies settle claim of misleading doctors on cancer survival data. BMJ 2016;353:i3361. [Ref.ID 100436]

13.

Erviti López J. Incertidumbres sobre los nuevos anticoagulantes orales en fibrilación auricular Irregularidades y lagunas en su autorización. Boletín de Información Farmacoterapéutica de Navarra 2016;24:1-12. [Ref.ID 100353]

14.

Chen R, Desai NR, Ross JS, Zhang W, Chau KH, Wayda B, Murugiah K, Lu DY, Mittal A, Krumholz HM, Hines HH. Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers. BMJ 2016;352:i637. [Ref.ID 100065]

15.

Christopoulos C. Questions about the reliability of ROCKET-AF anticoagulation data. BMJ 2016;352:i1039. [Ref.ID 100063]

16.

Cohen D. Rivaroxaban: can we trust the evidence?. BMJ 2016;352:i575. [Ref.ID 100048]

17.

Vigario A. Pfizer despide a 30 altos cargos en España por incumplir el código ético. El Economista 2015:1. [Ref.ID 100040]

18.

Anónimo. UK fines GlaxoSmithKline $54 million for pay-to-delay deals. DIA Daily 2016:1. [Ref.ID 99999]

19.

Gubar S. Living with cancer: a broken covenant with patients. N Y Times (Print) 2016:1. [Ref.ID 99979]

20.

Marciniak TA, Cherepanov V, Golukhova I, Hyun Kim M, Serebruany V. Drug discontinuation and follow-up rates in oral antithrombotic trials. JAMA Intern Med 2016;176:11 de enero. [Ref.ID 99961]